CD274 and lung carcinoma: Indeed, thrombocytopenia is a common toxicity of ICIs.18–20 One study reported that the number of PD-L1-expressing platelets was diminished in the blood of four patients with lung cancer treated with the anti-PD-L1 antibody atezolizumab within the first 7 days of therapy.21 Another study reported that the average time to onset of thrombocytopenia induced by ICIs was 70 days, and the average platelet count was 61×109/L, with an average decrease of 70% from baseline.19